secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001193125-23-205590
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verrica FDA approval of YCANTH for molluscum and Q2 net loss $11M; cash runway to Q1 2025
--------------------------------------------------------------------------------

- FDA approved YCANTH (cantharidin) on July 21 for molluscum in patients 2+; launch by Sep 2023.
- Closed $125M debt facility with OrbiMed; drew $50M, up to $75M additional; cash extends into Q1 2025.
- Q2 GAAP net loss $11.0M ($0.24/share) vs $10.2M loss in prior year; non-GAAP loss $9.4M.
- Expanding Part 2 enrollment of VP-315 Phase 2 trial for basal cell carcinoma to accelerate development.
- Cash and equivalents $55.1M at June 30, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312523205590/0001193125-23-205590-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312523205590/d512113d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-205590

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer